Drugs / dalazatide
dalazatide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02435342 | Oct 2014 → Mar 2015 | psoriasis | Kineta Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02446340 | Nov 2013 → Apr 2014 | — | Kineta Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dalazatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02435342 ↗ |
| Known as | Dalazatida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297738 ↗ |
| Known as | SHK-186 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297738 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297738 ↗ |
| Route | Subcutaneous | “Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.” NCT02435342 ↗ |